Cardiff Oncology Inc (CRDF) - Total Assets
Based on the latest financial reports, Cardiff Oncology Inc (CRDF) holds total assets worth $61.88 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check CRDF total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Cardiff Oncology Inc - Total Assets Trend (2004–2025)
This chart illustrates how Cardiff Oncology Inc's total assets have evolved over time, based on quarterly financial data. Check Cardiff Oncology Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Cardiff Oncology Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Cardiff Oncology Inc's total assets of $61.88 Million consist of 97.2% current assets and 2.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.2% |
| Accounts Receivable | $182.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Cardiff Oncology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CRDF market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cardiff Oncology Inc's current assets represent 97.2% of total assets in 2025, an increase from 0.0% in 2004.
- Cash Position: Cash and equivalents constituted 28.2% of total assets in 2025, up from 0.0% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Cardiff Oncology Inc Competitors by Total Assets
Key competitors of Cardiff Oncology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
Cardiff Oncology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.67 | 7.08 | 28.71 |
| Quick Ratio | 3.67 | 7.08 | 28.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $43.73 Million | $81.63 Million | $124.09 Million |
Cardiff Oncology Inc - Advanced Valuation Insights
This section examines the relationship between Cardiff Oncology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.83 |
| Latest Market Cap to Assets Ratio | 1.39 |
| Asset Growth Rate (YoY) | -36.3% |
| Total Assets | $61.88 Million |
| Market Capitalization | $86.14 Million USD |
Valuation Analysis
Above Book Valuation: The market values Cardiff Oncology Inc's assets above their book value (1.39x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Cardiff Oncology Inc's assets decreased by 36.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cardiff Oncology Inc (2004–2025)
The table below shows the annual total assets of Cardiff Oncology Inc from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $61.88 Million | -36.33% |
| 2024-12-31 | $97.19 Million | +19.05% |
| 2023-12-31 | $81.64 Million | -29.74% |
| 2022-12-31 | $116.19 Million | -22.30% |
| 2021-12-31 | $149.54 Million | +11.00% |
| 2020-12-31 | $134.73 Million | +929.51% |
| 2019-12-31 | $13.09 Million | -7.66% |
| 2018-12-31 | $14.17 Million | +15.36% |
| 2017-12-31 | $12.29 Million | -72.05% |
| 2016-12-31 | $43.95 Million | -38.49% |
| 2015-12-31 | $71.45 Million | +147.24% |
| 2014-12-31 | $28.90 Million | +6.41% |
| 2013-12-31 | $27.16 Million | +132.80% |
| 2012-12-31 | $11.66 Million | +1022.44% |
| 2011-12-31 | $1.04 Million | +102.89% |
| 2010-12-31 | $512.22K | -32.60% |
| 2009-12-31 | $760.00K | -113.67% |
| 2005-12-31 | $-5.56 Million | +421.34% |
| 2004-12-31 | $-1.07 Million | -- |
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in… Read more